

# Medicare Advantage Medical Policy



## Corneal Collagen Cross-linking – Medicare Advantage

### Medicare Advantage Plan

- Medicare Plus Blue<sup>SM</sup>
- BCN Advantage<sup>SM</sup>

**UM Committee Approval Date:** 7/17/2024

**Effective Date:** 7/17/2024

### Description

Corneal collagen cross-linking (CXL) is a photochemical procedure approved by the Food and Drug Administration for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Keratoconus is a dystrophy of the cornea characterized by progressive deformation (steepening) of the cornea while corneal ectasia is keratoconus that occurs following refractive surgery. Both conditions lead to functional loss of vision and need for corneal transplantation.

### Coverage Determination

BCBSM/BCN follows guidance from the Centers for Medicare and Medicaid Services (CMS) when performing organization (coverage) determinations for Medicare Advantage plans members. CMS Medicare statutes, regulations, manuals, National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) provide the clinical guidelines for coverage determinations. When CMS Medicare guidance is not fully established, BCBSM/BCN may use LCD/LCAs outside the services area, independent criteria, internal coverage criteria, or research from independent medical research repositories (i.e., Hayes) for coverage determinations. BCBSM/BCN internal medical coverage policies are developed and based on current evidence in widely accepted treatment guidelines or clinical literature; in addition, they address how the clinical benefits are highly likely to outweigh any clinical harms, including (but not limited to) delayed or decreased access to services.

### The following is applicable for this medical policy:

After searching the Medicare Coverage Database, it was determined that CMS does **not** have manual or NCD/LCD/LCA clinical guidelines for coverage determination of the services or items related to the codes in the policy. BCBSM/BCN internal policy coverage criteria will be applied. This service may be medically necessary when the criteria are met.

| Code  | Description   | NCD  | LCD/LCA | Additional Guidance   |
|-------|---|------|---------|---|
| 0402T | Collagen cross-linking of cornea, including removal of the corneal epithelium and intraoperative pachymetry when performed (report medication separately) | None | None    | As no NCDs or LCDs are available for guidance refer to the BCBSM/BCN policy:<br><br><i>Corneal Collagen Cross-linking</i><br><br><b>Note:</b> Policy attached below |
| J2787 | Riboflavin 5'-phosphate, ophthalmic solution, up to 3 ml  |      |         |   |

CPT® codes, descriptions and materials are copyrighted by the American Medical Association (AMA).  
 HCPCS® codes, descriptions and materials are copyrighted by Centers for Medicare and Medicaid Services (CMS).

The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by CMS are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. MAC jurisdiction for purposes of local coverage determinations is governed by the geographic service area where the Medicare Advantage plan is contracted to provide the service. Please refer to the Medicare Coverage Database website at <https://www.cms.gov/medicare-coverage-database/search.aspx> for the most current applicable NCD, LCD, LCA, and CMS Online Manual System/Transmittals.

---

### Important Reminder

BCBSM/BCN follows CMS Medicare coverage guidance to limit coverage to items and services that are reasonable and necessary for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body member. Medicare Advantage medical coverage policies list the criteria our clinicians use to decide when medical services are considered “reasonable and necessary.”

**Note:** U.S. Food and Drug Administration (FDA) approval for a specific indication or the issuance of a CPT code is not sufficient for a procedure to be considered medically reasonable and necessary. Similarly, the presence of a procedure/device code or payment amount for the service in the Medicare fee schedule does not necessarily indicate coverage. If a service is deemed not reasonable and necessary, to treat illness or injury for any reason (including lack of safety and efficacy because it is an experimental procedure, etc.), the procedure is considered not covered.

**Disclaimer:** The Medical Coverage Policies are reviewed by the BCBSM/BCN Utilization Management Committee. Policies in this document may be modified by a member’s coverage document. The existence of the medical policy is not an authorization, certification, explanation of benefits, or a contract for the services, devices, or drugs that is referenced in the medical policy. Medical policies do not constitute medical advice and do not guarantee any results or outcomes. Medical policy is not intended to replace independent medical judgment for treatment of individuals. Treating physicians and health care providers are solely responsible for determining what care to provide to their patients. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test, or procedure over another.

Pursuant to Section 1557 and Section 504, Blue Cross does not discriminate on the basis of race, color, national origin, age, disability, or sex (including sex characteristics, intersex traits; pregnancy or related conditions; sexual orientation; gender identity, and sex stereotypes). This includes our rules, benefit designs and medical policies.

---

### **BCBSM/BCN Medicare Advantage Policy History**

| <b>Policy Effective Date</b> | <b>UM Committee Approval Date</b> | <b>Comments</b>             |
|------------------------------|-----------------------------------|-----------------------------|
| 07/17/2024                   | 07/17/2024                        | Medicare policy established |

## Medical Policy



Nonprofit corporations and independent licensees  
of the Blue Cross and Blue Shield Association

**Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate certificate or contract for benefit information. This policy may be updated and is therefore subject to change.**

---

**\*Current Policy Effective Date: 3/1/24**  
(See policy history boxes for previous effective dates)

### **Title: Corneal Collagen Cross-linking**

---

#### **Description/Background**

Corneal collagen cross-linking (CXL) is a photochemical procedure approved by the Food and Drug Administration for the treatment of progressive keratoconus and corneal ectasia following refractive surgery. Keratoconus is a dystrophy of the cornea characterized by progressive deformation (steepening) of the cornea while corneal ectasia is keratoconus that occurs following refractive surgery. Both conditions lead to functional loss of vision and need for corneal transplantation.

#### **Treatment of Keratoconus and Ectasia**

The initial treatment for keratoconus often consists of hard contact lenses. A variety of keratorefractive procedures have also been attempted, broadly divided into subtractive and additive techniques. Subtractive techniques include photorefractive keratectomy or laser in situ keratomileusis (LASIK), although generally, results of these techniques have been poor. Implantation of intrastromal corneal ring segments is an additive technique in which the implants are intended to reinforce the cornea, prevent further deterioration, and potentially obviate the need for penetrating keratoplasty. Penetrating keratoplasty (i.e., corneal grafting) is the last line of treatment. About 20% of patients with keratoconus will require corneal transplantation. All of these treatments attempt to improve the refractive errors but are not disease-modifying.

Treatment options for ectasia include intraocular pressure-lowering drugs, and intracorneal ring segments. Frequently, a penetrating keratoplasty is required.

None of the currently available treatment options for keratoconus and corneal ectasia halt the progression of disease and corneal transplantation is the only option available when functional vision can no longer be achieved.

Corneal collagen cross-linking (CXL) has the potential to slow the progression of disease. It is performed with the photosensitizer riboflavin (vitamin B<sub>2</sub>) and ultraviolet A (UVA) irradiation. There are 2 protocols for CXL.

1. Epithelium-off CXL (also known as "epi-off"): In this method, about 8 mm of the central corneal epithelium is removed under topical anesthesia to allow better diffusion of the

photosensitizer riboflavin into the stroma. Following de-epithelialization, a solution with riboflavin is applied to the cornea (every 1-3 minutes for 30 minutes) until the stroma is completely penetrated. The cornea is then irradiated for 30 minutes with ultraviolet A 370 nm, a maximal wavelength for absorption by riboflavin, while the riboflavin continues to be applied. The interaction of riboflavin and UVA causes the formation of reactive oxygen species, leading to additional covalent bonds (cross-linking) between collagen molecules, resulting in stiffening of the cornea. Theoretically, by using a homogeneous light source and absorption by riboflavin, the structures beyond a 400-micron thick stroma (endothelium, anterior chamber, iris, lens, retina) are not exposed to an ultraviolet dose that is above the cytotoxic threshold.

2. Epithelium-on CXL (also known as “epi-on” or transepithelial): In this method, the corneal epithelial surface is left intact (or may be partially disrupted) and a longer riboflavin loading time is needed.

Currently, the only CXL treatment approved by the Food and Drug Administration (FDA) is the epithelium-off method; there are no FDA-approved CXL treatments using the epithelium-on method. CXL is being evaluated primarily for corneal stabilization in patients with progressive corneal thinning, such as keratoconus and corneal ectasia following refractive surgery. CXL may also have anti-edematous and antimicrobial properties.

---

## **Regulatory Status:**

In 2016, riboflavin 5'-phosphate in 20% dextran ophthalmic solution (Photrexa Viscous™; Avedro) and riboflavin 5'-phosphate ophthalmic solution (Photrexa™; Avedro) were approved by the FDA for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia after refractive surgery.(1)

---

## **Medical Policy Statement**

The application of riboflavin with ultraviolet light for the treatment of keratoconus, also called corneal cross-linking, is considered established for individuals meeting specific selection criteria.

---

## **Inclusionary and Exclusionary Guidelines**

### **Inclusions:**

Corneal collagen cross-linking using riboflavin and ultraviolet A may be considered medically necessary when one of the following conditions have been met:

- Keratoconus, when the diagnosis has been established and progression of the disease is considered likely
- Corneal ectasia after refractive surgery

### **Exclusions:**

Corneal collagen cross-linking using riboflavin and ultraviolet A is considered experimental/investigational for all other indications.

---

**CPT/HCPCS Level II Codes** *(Note: The inclusion of a code in this list is not a guarantee of coverage. Please refer to the medical policy statement to determine the status of a given procedure)*

**Established codes:**

0402T            J2787

**Other codes (investigational, not medically necessary, etc.):**

N/A

---

**Rationale**

**CORNEAL COLLAGEN CROSS-LINKING FOR KERATOCONUS**

**Clinical Context and Therapy Purpose**

Keratoconus is a bilateral dystrophy characterized by progressive ectasia (paracentral steepening and stromal thinning) that impairs visual acuity. While frequently diagnosed at a young age, the progression of keratoconus is variable. Results from a longitudinal study of over 900 individuals with keratoconus showed that, there was a decrease of 2 high and 4 low-contrast letters in best-corrected visual acuity over 7-years of follow-up.(2,3) About 1 in 5 patients showed a decrease of 10 or more letters in high-contrast visual acuity and one-third of patients showed a decrease of 10 or more letters in low-contrast visual acuity.

Per American Academy of Ophthalmology, treatment of progressive keratoconus is a step ladder with the least invasive measure at the starting point. Indications to maneuver care, through the less invasive steps, include patients inability to achieve adequate visual function, reasonable comfort or a stable fit.(19)

Glasses have traditionally been the first step to correct vision, moving onto contact lenses as the disease progresses. Intrastromal corneal ring segments (ICRS) may help improve contact lens tolerance and vision by reducing contour irregularities. When cataract surgery is indicated, intraocular lenses can correct myopia and regular corneal astigmatism in certain situations. The indications for considering a keratoplasty include the patients inability to achieve adequate visual function, reasonable comfort, or a stable fit with less invasive therapies.

According to the new American Academy of Ophthalmology, the primary purpose of crosslinking is to halt the progression of ectasia by improving the structural integrity of the cornea and can be considered in the early stages of the disease.(20)

The purpose of corneal collagen cross-linking using riboflavin and ultraviolet A irradiation in individuals with keratoconus is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does corneal collagen cross-linking using riboflavin and ultraviolet A in individuals with keratoconus improve net health outcomes?

The following PICO was used to select literature to inform this review.

**Populations**

The relevant population of interest is individuals with progressive keratoconus.

## **Intervention**

The treatment being considered is corneal collagen cross-linking with riboflavin and ultraviolet A irradiation, which is performed by an ophthalmologist in an outpatient clinical setting.

## **Comparators**

The comparators of interest are observation, rigid or specialty contact lens, intracorneal ring segments, or corneal transplant.

## **Outcomes**

The outcomes of interest are change in disease status, functional outcomes, and treatment-related morbidity. Positive outcomes include slowing of disease progression and improvement in visual acuity and other ocular measurements. Negative outcomes include infection, adverse reactions, and need for alternative treatment, including corneal transplant.

Follow-up of at least 1 year is needed to assess outcomes.

## **Visual acuity definitions**

Best spectacle-corrected visual acuity is the best vision correction that can be achieved with glasses as measured on the standard Snellen eye chart.

Best corrected visual acuity is the best vision correction that can be achieved with any visual correction (e.g., glasses, contact lenses, keratotomy) as measured on the standard Snellen eye chart.

Uncorrected visual acuity is the vision correction without visual correction as measured on the standard Snellen eye chart.

## **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

## **Review of Evidence**

### **Randomized Controlled Trials**

Hersh et al (2017) reported combined results from 2 open-label trials which informed FDA approval of corneal collagen cross-linking for treatment of keratoconus.(4) The studies randomized 205 patients to CXL (n=102) or a sham procedure (n=103). At 1 year follow-up, those in the treatment group had a significant decrease in maximum corneal curvature (1.0); the between-group difference in maximum corneal curvature change was 2.6 D (p<0.001). Mean corrected distance visual acuity improved significantly more in the treatment group (5.7 Logarithm of the Minimum Angle of Resolution logMAR) than in the control group (2.2 logMAR; between-group difference, 3.5 logMAR; p<0.01). A similar finding, though statistically insignificant, was observed for mean uncorrected distance visual acuity, with the treatment group improving by 4.4 logMAR, compared with the control group (2.6 logMAR; between-group

difference, 1.8 logMAR). Endothelial cell count did not change significantly from baseline to 1 year in either group. Symptom and quality of life measures that were significantly improved from baseline at 1-year follow-up included reductions in difficulty driving, difficulty reading, double vision, vision fluctuations, glare and foreign body sensations in the corneal collagen cross-linking group; outcomes for the sham group were not reported. The trial was limited in that patients in the control group were allowed to switch to corneal collagen cross-linking treatment after 3 months; thus, their data were imputed based on the last observation carried forward method. Also, in the control group, patients did not undergo removal of their epithelium.

### **Systematic Reviews**

McAnena et al (2017) reported on the results of a systematic review and a meta-analysis assessing the efficacy of corneal collagen cross-linking treatment for keratoconus in pediatric patients.(5) A total of 13 articles, published between May 2011 and December 2014, examining 490 eyes of 401 patients (mean age, 15.25 years), were included in the meta-analysis. Bias assessment of individual studies was not included. Reviewers reported a significant improvement in best-corrected visual acuity at 6 months (standardized mean difference[SMD], -0.66; 95% confidence interval [CI], -1.22 to -0.11;  $p=0.02$ ), which was maintained at one year (SMD, -0.69; 95% CI, -1.15 to -0.22;  $p<0.01$ ). Two-year data were available for three studies (N=131 eyes) and the improvement in best-corrected visual acuity remained significant (SMD, -1.03; 95% CI, -2 to -0.06;  $p=0.04$ ).

### **Nonrandomized Studies**

Longer-term follow-up ranging from 2 to 10 years has been reported in cohort studies and case series conducted in Europe, where corneal collagen cross-linking has been performed for a greater number of years. Indications for treatment typically include progression of steepening (increase in maximum corneal curvature by at least 1 D in 1 year), deteriorating visual acuity, or the need to be fitted for new contact lenses more than once in 2 years. The largest and longest series to date are described next.

Toprak et al (2017) retrospectively analyzed 29 eyes from pediatric patients (age range, 10-17 years) whose progressive keratoconus was treated with unilateral corneal collagen cross-linking treatment.(6) From baseline to 2-year follow-up, there was a significant decrease in mean corrected distance visual acuity (0.34 logMAR to 0.13 logMAR;  $p<0.001$ ). Maximum keratometry measures decreased from baseline 54.65 to 53.25 at 2 years ( $p=0.034$ ), while anterior chamber parameters, corneal thickness, and corneal volume were not significantly affected by corneal collagen cross-linking after 2 years ( $p>0.05$ ). Several parameters of the Scheimpflug imaging system were improved following corneal collagen cross-linking treatment: index of surface variance decreased from 69.75 at baseline to 62.95 at 2 years ( $p=0.004$ ); keratoconus index decreased from 1.16 to 1.14 ( $p=0.001$ ); center keratoconus index decreased from 1.05 to 1.04 ( $p=0.004$ ); and index of height decentration decreased from 0.056 to 0.042 ( $p=0.001$ ). The radius of minimum curvature increased significantly from baseline to 2 years (6.21 to 6.36;  $p=0.007$ ), although 2 other indices (indices of height and vertical asymmetry) did not change significantly. The authors noted that follow-up beyond 2 years is required to make long-term assessments of corneal collagen cross-linking as a treatment for keratoconus but concluded that their results seemed favorable for postoperative outcomes.

Badawi et al (2017) published a prospective nonrandomized observational study of accelerated corneal collagen cross-linking to treat pediatric patients with keratoconus.(7) Of the 25 patients (33 eyes) enrolled, 80% were male, and most patients (n=17) received unilateral corneal collagen cross-linking, administered with VibeX Rapid solution and Vega



CBM X-Linker. The group's mean unaided and aided visual acuity were significantly improved at all time points (3, 6, and 12 months). At 12-month follow-up, the mean unaided visual acuity score was 0.34, which was a significant decrease compared with preoperative mean score (0.54;  $p < 0.001$ ). For aided visual acuity, there was a similar decrease from preoperative (0.36) to 12-month (0.17) time points ( $p < 0.001$ ). Mean corneal astigmatism values also decreased significantly (preoperative 2.4 D decreased to 2.01 D at 12 months;  $p < 0.001$ ). The mean maximum corneal curvature showed an average flattening of 1.2 D in 1 year (49.12 D decreasing to 47.9 D;  $p < 0.001$ ); the authors reported significant improvements in other measures such as central pachymetry, maximum anterior elevation, average progression indices, and Q values. A limitation of the study was the slight increase observed in posterior surface elevation, which, contrary to other study measures, showed no significant positive effect 12 months after accelerated corneal collagen cross-linking ( $p = 0.9$ ). Advising further study of the procedure, the authors noted that the unusual result might be accounted for by the choice of Pentacam as a corneal analysis tool because there might have been corneal artifacts present during evaluation.

Knutsson et al (2018) published a prospective cohort study of 43 patients (52 eyes) between the ages of 12 and 17 who underwent corneal collagen cross-linking as a treatment for keratoconus in 1 or both eyes.<sup>(8)</sup> Two-year outcomes were reported for all patients, although longer-term (up to 7 years) follow-up was available for 21 eyes. At 2 years, overall mean maximum corneal curvature decreased from  $59.30 \pm 7.08$  to  $57.07 \pm 6.46$  ( $p < 0.001$ ), and overall mean uncorrected visual acuity and best spectacle-corrected visual acuity decreased, although not significantly. Additional analyses were conducted of patients whose eyes had maximum corneal curvature values of 60 D or greater ( $n = 25$ ), compared with those whose keratometry was less severe ( $< 60$  D). As with the overall findings, mean maximum corneal curvature were significantly decreased for both cohorts, while neither uncorrected visual acuity nor best spectacle-corrected visual acuity measures changed significantly at 1 or 2 years. In patients with advanced keratoconus, mean maximum corneal curvature decreased from 64.94 (95% CI, 62.94 to 66.94) to 62.25 (95% CI, 60.55 to 63.95) at 2 years ( $p < 0.001$ ); for the less-advanced cohort, mean maximum corneal curvature decreased from 53.88 (95% CI, 52.48 to 55.28) at baseline to 52.08 (95% CI, 50.68 to 53.48) at 2 years ( $p < 0.001$ ). While most findings were favorable for the efficacy of corneal collagen cross-linking in treating even severe keratometry, the authors noted that the study was limited by the use of 2 pachymetric measurement techniques (optical coherence tomography and ultrasound) rather than a single technique across the study. Further, the lack of full long-term data for all patients limited the study to reporting only 2-year outcomes.

Papaoannou et al (2016) retrospectively analyzed 377 eyes of 336 patients (mean age, 15 years) who underwent corneal collagen cross-linking for progressive keratoconus.<sup>(9)</sup> There was a significant improvement in mean best spectacle-corrected visual acuity from 0.33 to 0.27 logMAR ( $p < 0.05$ ). The authors found that the benefits of corneal collagen cross-linking in stabilizing keratoconus were maintained for more than 2 years in most pediatric eyes.

Padmanabhan et al (2017) published follow-up results from the retrospective study previously mentioned of 377 eyes in 336 pediatric patients.<sup>(10)</sup> Of 59 eyes for which investigators had longer-term follow-up data (4 to 6.7 years), 30.9% showed worsening corrected distance visual acuity, and 24% showed corneal steepening of greater than 1 D (maximum corneal curvature). These results showed the majority of patients still experienced improvements or stabilization of keratoconus-related outcomes after corneal collagen cross-linking but suggested that long-term there may be less efficacy.

Raiskup-Wolf et al (2008) reported on outcomes of 241 eyes (272 patients) treated with corneal collagen cross-linking, with a minimum of six months of follow-up.(11) Follow-up examinations were performed at 1, 6, and 12 months, and then annually. Mean follow-up was 26 months, with a range of 12 months (n=142) to 6 years (n=5). In the first year (n=142), steepening (maximum corneal curvature) improved or remained stable in 86% of eyes, and best-corrected visual acuity improved by at least 1 line in 53% of the eyes. Three years after treatment (n=33), maximum corneal curvature improved by a mean of 2.57 D in 67% of eyes while best-corrected visual acuity improved by at least one line in 58% of eyes. In 2015, the same group published a 10-year follow-up of corneal collagen cross-linking treatment in 34 eyes (24 patients) with progressive keratoconus.(12) Mean patient age at the time of treatment was 28 years (range, 14-42 years). Corneal steepening improved slightly between baseline and 10-year follow-up ( $p<0.001$ ), while corrected distance visual acuity improved by 0.14 logMAR ( $p=0.002$ ). Two eyes had repeat corneal collagen cross-linking, one after five years and one after ten years, without adverse sequelae. One of the 34 eyes treated developed a permanent corneal scar. These studies were limited by their retrospective designs and the small number of cases with extended follow-up.

A publication from the Siena Eye Cross Study (2010) reported on 52-month mean follow-up (range, 48-60 months) for 44 keratoconic eyes treated with corneal collagen cross-linking.(13) Follow-up evaluations were performed at 1, 2, 3, 6, 12, 24, 36, 48, and 60 months after corneal collagen cross-linking. Topographic analysis showed the following mean Kreading reductions: -1.96 D after 1 year, -2.12 D after 2 years, -2.24 D after 3 years, and -2.26 D after 4 years of follow-up. By comparison, in fellow eyes untreated for the first 24 months, the mean K value increased by 1.2 D at 1 year and 2.2 D at 2 years. In treated eyes, uncorrected visual acuity improved by a mean of 2.41 lines after 12 months, 2.75 lines after 24 months, 2.80 lines after 36 months, and 2.85 lines after 48 months. There was no significant decrease in endothelial cell density, central corneal thickness, or intraocular pressure over follow-up. Temporary adverse events included stromal edema in the first 30 days (70% of patients) and temporary haze (9.8% of patients). No persistent adverse events were observed.

### **Section Summary: Corneal Collagen Cross-Linking for Keratoconus**

The evidence for corneal collagen cross-linking for keratoconus includes RCTs, systematic reviews, and nonrandomized studies. Overall results showed long-term reduction in corneal curvature and less significant improvements in visual acuity, although some studies found significant improvement in Best spectacle-corrected visual acuity up to at least 2 years.

### ***Corneal Collagen Cross-Linking for Ectasia***

Ectasia (also known as keratectasia, iatrogenic keratoconus, or secondary keratoconus) is a serious long-term complication of laser in situ keratomileusis (LASIK) surgery and photorefractive keratectomy (PRK). It is similar to keratoconus but occurs postoperatively and primarily affects older populations. It may result from unrecognized preoperative keratoconus or, less frequently, from the surgery itself. Similar to keratoconus, it is characterized by progressive thinning and steepening of the cornea, resulting in corneal optical irregularities and loss of visual acuity.

The purpose of corneal collagen cross-linking using riboflavin and ultraviolet A irradiation in individuals with ectasia is to provide a treatment option that is an alternative to or an improvement on existing therapies.

The question addressed in this evidence review is: Does corneal collagen cross-linking using riboflavin and ultraviolet A in individuals with corneal ectasia improve net health outcomes?

The following PICO was used to select literature to inform this review.

### **Populations**

The relevant population of interest is individuals with corneal ectasia.

### **Intervention**

The treatment being considered is corneal collagen cross-linking with riboflavin and ultraviolet A irradiation, which is performed by an ophthalmologist in an outpatient clinical setting.

### **Comparators**

The comparators of interest are observation, rigid or specialty contact lens, intracorneal ring segments, or corneal transplant.

### **Outcomes**

The outcomes of interest are change in disease status, functional outcomes, and treatment-related morbidity. Positive outcomes include slowing of disease progression and improvement in visual acuity and other ocular measurements. Negative outcomes include infection, adverse reactions, and need for alternative treatment, including corneal transplant.

Follow-up of at least 1 year is needed to assess outcomes.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess long-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

### **Review of Evidence**

#### **Randomized Controlled Trials**

A trial reported by Hersh et al (2017), used to inform FDA approval of corneal collagen cross-linking for treatment of corneal ectasia enrolled 179 patients treated for post-surgical corneal ectasia. (14) The prospective, multicenter controlled trial randomized 91 patients to treatment with standard CXL and 88 patients to a sham procedure which administered riboflavin alone and did not require the removal of the epithelium. The primary end point was 1-year change in Kmax, which was a mean 0.7-D decrease in the CXL group and an 0.6-D increase in the control group (between-group difference, 1.3 D;  $p < 0.001$ ). A significantly greater improvement in CDVA was observed for the CXL group (5.0 logMAR gained) than for the control group (0.3 logMAR lost;  $p < 0.001$ ), as was the case with UDVA, for which the between-group difference was 4.6 letters ( $p < 0.001$ ). There was no significant difference between treatment and control groups for either MRSE myopia or for endothelial cell density, and fewer than 5% of eyes had adverse events. Over half of patients (68%) reported corneal stromal haze or demarcation line. The trial was limited by the LOCF analysis required for the control patients who elected to receive treatment after three months; also, because only four patients received photorefractive keratectomy surgery, comparison between types of surgery and effects of post-surgery CXL were precluded.

Wittig-Silva et al (2008) reported the first randomized controlled trial (RCT) of corneal CXL.(15) Three-year results were published in 2014.(16) Recruitment for the trial was completed in 2009 with 50 eyes randomized to CXL and 50 randomized to untreated control. To be eligible for enrollment, clear evidence of progression of the ectasia over the preceding 6 to 12 months was required. Progression was confirmed if at least 1 of the following criteria were met: an increase of at least 1 D in the steepest simulated keratometry reading (K-max); an increase in astigmatism determined by manifest subjective refraction of at least 1 D; an increase of 0.50 D in MRSE; or a 0.1 mm or more decrease in back optic zone radius of the best fitting contact lens. At the time of analysis for the 2008 report, 20 eyes had reached 1-year follow-up. The 3-year results included 46 CXL and 48 control eyes. Last observation carried forward was used for 26 eyes, including 17 eyes from the control group with progressive disease that underwent compassionate use CXL or corneal transplantation. In the CXL group there was a flattening of Kmax by -1.03 D, compared with an increase in Kmax of 1.75 in the control group. One eye in the CXL group progressed by more than 2 D, compared with 19 eyes in the control group. Uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA) improved in the CXL-treated eyes at 1, 2, and 3 years.

### **Section Summary: Corneal Collagen Cross-Linking for Ectasia**

Evidence for corneal collagen cross-linking for corneal ectasia includes RCTs. Results showed improvement in uncorrected distance visual acuity, corrected distance visual acuity, Best spectacle-corrected visual acuity, and maximum corneal curvature compared to sham after at least 12 months. In addition, a higher proportion of participants in the corneal collagen cross-linking group had a  $\geq 15$ -letter improvement with Best spectacle-corrected visual acuity than in the sham group.

### **Adverse Events**

The safety analysis conducted by FDA included 512 eyes (293 keratoconus, 219 corneal ectasia) in 364 patients who received CXL treatment.(17) As described earlier, the procedure involves removing the corneal epithelium to enhance the riboflavin solution's penetration. As a result, patients may develop a range of ocular adverse reactions, including corneal opacity (haze), corneal epithelial defects, punctate keratitis, corneal striae, eye pain, reduced visual acuity, blurred vision, dry eye, and photophobia among others. Most adverse reactions resolved in the first month, while others took up to 12 months to resolve. However, in 1% to 6% of patients, these adverse reactions could continue beyond 12 months.

### **SUMMARY OF EVIDENCE**

For individuals who have progressive keratoconus who receive collagen cross-linking (CXL) using riboflavin and ultraviolet A, the evidence includes randomized controlled trials (RCTs), systematic reviews, and nonrandomized studies. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. Based on RCT evidence used to inform FDA approval, corneal collagen cross-linking was associated significant improvements in corneal curvature score and corrected distance visual acuity and non-significant improvement in uncorrected distance visual acuity compared with sham treatment after 1 year follow-up. Long-term RCT follow-up is needed. Several non-randomized studies measured visual acuity and found significant and lasting improvements in corrected visual acuity and other measures with corneal collagen cross-linking. The adverse events associated with CXL include corneal opacity (haze), corneal epithelial defects, and other ocular findings. Most adverse events resolved in the first month but, in a few (1%-6%) patients, continued for 6 to 12 months. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have corneal ectasia after refractive surgery who receive CXL using riboflavin and ultraviolet A, the evidence includes RCTs. Relevant outcomes are change in disease status, functional outcomes, and treatment-related morbidity. RCT evidence, used to inform FDA approval, found corneal collagen cross-linking associated significant improvements in corneal curvature score, corrected distance visual acuity and uncorrected distance visual acuity after 1 year follow-up when compared with sham treatment. Another trial that followed patients up to 3 years and saw continued improvement in visual acuity with corneal collagen cross-linking. Additional long-term follow-up for visual acuity outcomes is needed. The adverse events associated with CXL include corneal opacity (haze), corneal epithelial defects, and other ocular findings. Most adverse events resolved in the first month, but, in a few (1%-6%) patients, continued for 6 to 12 months. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

---

## **Supplemental information**

### **PRACTICE GUIDELINES AND POSITION STATEMENTS**

#### **The American Academy of Ophthalmology**

The American Academy of Ophthalmology (2017) issued recommendations regarding the use of CXL as follows:(20)

“Cross-Linking (CXL) has long term data supporting its safety and stability and should be considered for patients with early Keratoconus and at risk of progression to arrest or slow progression in its earliest stage.”

#### **National Institute for Health and Care Excellence**

The National Institute for Health and Care Excellence (2013) issued guidance on corneal collagen cross-linking (CXL) using riboflavin and ultraviolet A, updating its guidance based on a 2009 systematic review of primarily low-quality evidence; review authors declared no financial conflicts of interest.(18) The 2013 guidance stratified NICE recommendations for corneal CXL as follows:

“Most of the published evidence on photochemical corneal collagen cross-linkage (CXL) using riboflavin and ultraviolet A (UVA) for keratoconus and keratectasia relates to the technique known as 'epithelium-off' CXL'. 'Epithelium-on (transepithelial) CXL' is a more recent technique and less evidence is available on its safety and efficacy. Either procedure (epithelium-off or epithelium-on CXL) can be combined with other interventions, and the evidence base for these combination procedures (known as 'CXL-plus') is also limited. Therefore, different recommendations apply to the variants of this procedure, as follows:

- 1.1 Current evidence on the safety and efficacy of epithelium off CXL for keratoconus and keratectasia is adequate in quality and quantity. Therefore, this procedure can be used provided that normal arrangements are in place for clinical governance, consent and audit.
- 1.2 Current evidence on the safety and efficacy of epithelium-on (transepithelial) CXL, and the combination (CXL-plus) procedures for keratoconus and keratectasia is inadequate in quantity and quality. Therefore, these procedures should only be used with special arrangements for clinical governance, consent and audit or research”.

## U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS

Not applicable.

## ONGOING AND UNPUBLISHED CLINICAL TRIALS

Some currently ongoing trials that might influence this review are listed in Table 5.

**Table 5. Summary of Key Trials**

| NCT No.                  | Trial Name   | Planned Enrollment | Completion Date                                |
|--------------------------|--|--------------------|--|
| <b>Ongoing</b>           |  |                    |  |
| NCT01708538 <sup>a</sup> | Phase III Study of Corneal Collagen Cross-linking Using Two Different Techniques   | 30                 | Oct 2024                                       |
| NCT03531047              | A Prospective, Controlled Study of Refractive Corneal Cross-linking for Progressive Keratoconus  | 52                 | Nov 2021<br>(status=Unknown as of Sept 2020)   |
| NCT01112072              | Randomized Study of Safety and Efficacy of Corneal Collagen Crosslinking and Intacs for Treatment of Keratoconus and Corneal Ectasia   | 160                | Dec 2025                                       |
| NCT03319082 <sup>a</sup> | A Phase IV Observational Registry to Assess the Durability of Effect of Corneal Collagen Cross-linking With Photrexa Viscous, Photrexa, and the KXL System in Patients With Corneal Ectasia Following Refractive Surgery | 200                | Feb 2026                                       |
| NCT01604135              | Collagen Crosslinking for Keratoconus – a Randomized Controlled Clinical Trial   | 200                | April 2022                                     |
| NCT03760432              | Clinical Trial of Laser Custom Corneal Collagen Cross-Linking in Keratoconus   | 100                | Dec 2025                                       |
| NCT00560651              | German Corneal Cross-Linking Registry  | 7500               | Nov 2027                                       |
| <b>Unpublished</b>       |  |                    |  |
| NCT01344187 <sup>a</sup> | A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus           | 236                | Jun 2016<br>(updated 04/26/21)                 |
| NCT01972854 <sup>a</sup> | A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus           | 92                 | Apr 2017<br>(terminated;<br>updated 04/26/21 ) |

NCT: national clinical trial

<sup>a</sup> Denotes industry-sponsored or cosponsored trial

<sup>b</sup> Terminated to initiate FDA and IND-cleared study protocol.

---

## Government Regulations

### National:

There is no National Coverage Determination.

There is no assigned fee for J2787 on the Medicare fee schedule.

### Local:

There is no Local Coverage Determination.

*(The above Medicare information is current as of the review date for this policy. However, the coverage issues and policies maintained by the Centers for Medicare & Medicare Services [CMS, formerly HCFA] are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. For the most current information, the reader should contact an official Medicare source.)*

---

## Related Policies

Refractive Keratoplasties and Implantation of Intrastromal Corneal Ring Segments

---

## References

1. Avedro Inc. Photorexa® Viscous and Photorexa® Prescribing Label; retrieved February 10, 2020 from: [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2016/203324s000lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203324s000lbl.pdf).
2. Davis LJ, Schechtman KB, Wilson BS et al. Longitudinal changes in visual acuity in keratoconus. *Invest Ophthalmol Vis Sci* 2006; 47(2):489-500.
3. McMahan TT, Edrington TB, Szczotka-Flynn L et al. Longitudinal changes in corneal curvature in keratoconus. *Cornea* 2006; 25(3):296-305.
4. Hersh PS, Stulting RD, Muller D, et al. United States multicenter clinical trial of corneal collagen crosslinking for keratoconus treatment. *Ophthalmology*. Sep 2017;124(9):1259-1270. PMID 28495149
5. McAnena L, Doyle F, O'Keefe M. Cross-linking in children with keratoconus: a systematic review and meta-analysis. *Acta Ophthalmol*. Sep 28 2016. PMID 27678078
6. Toprak I, Yaylali V, Yildirim C. Visual, topographic, and pachymetric effects of pediatric corneal collagen cross-linking. *J Pediatr Ophthalmol Strabismus*. Mar 1 2017;54(2):84-89. PMID 27668869
7. Badawi AE. Accelerated corneal collagen cross-linking in pediatric keratoconus: One year study. *Saudi J Ophthalmol*. Jan-Mar 2017;31(1):11-18. PMID 28337057
8. Knutsson KA, Paganoni G, Matuska S, et al. Corneal collagen cross-linking in paediatric patients affected by keratoconus. *Br J Ophthalmol*. Feb 2018;102(2):248-252. PMID 28655729
9. Papaioannou L, Miligkos M, Papathanassiou M. Corneal Collagen Cross-Linking for Infectious Keratitis: A Systematic Review and Meta-Analysis. *Cornea*. Jan 2016;35(1):62-71. PMID 26509768
10. Padmanabhan P, Rachapalle Reddi S, Rajagopal R, et al. Corneal collagen cross-linking for keratoconus in pediatric patients-long-term results. *Cornea*. Feb 2017; 36(2): 138-143. PMID 28060058
11. Raiskup-Wolf F, Hoyer A, Spoerl E et al. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. *J Cataract Refract Surg* 2008; 34(5):796-801. PMID 18471635
12. Raiskup F, Theuring A, Pillunat LE, et al. Corneal collagen crosslinking with riboflavin and ultraviolet-A light in progressive keratoconus: ten-year results. *J Cataract Refract Surg*. Jan 2015;41(1):41-46. PMID 25532633
13. Caporossi A, Mazzotta C, Baiocchi S et al. Long-term results of riboflavin ultraviolet a corneal collagen cross-linking for keratoconus in Italy: the Siena eye cross study. *Am J Ophthalmol* 2010; 149(4):585-93. PMID 20138607
14. Hersh PS, Stulting RD, Muller D, et al. U.S. multicenter clinical trial of corneal collagen crosslinking for treatment of corneal ectasia after refractive surgery. *Ophthalmology*. Oct 2017;124(10):1475-1484. PMID 28655538
15. Wittig-Silva C, Whiting M, Lamoureux E et al. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. *J Refract Surg* 2008; 24(7):S720-5. PMID 18811118
16. Wittig-Silva C, Chan E, Islam FM et al. A Randomized, Controlled Trial of Corneal Collagen Cross-Linking in Progressive Keratoconus: Three-Year Results. *Ophthalmology* 2014; 121(4): 812-21. PMID 24393351
17. Center for Drug Evaluation and Research. Application Number 203324Orig2s000. Summary Review. 2015;

[https://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2016/203324Orig2s000SumR.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/203324Orig2s000SumR.pdf).

Accessed February 4, 2022.

18. National Institute for Health and Care Excellence (NICE). Photochemical corneal collagen cross-linkage using riboflavin and ultraviolet A for keratoconus and keratectasia [IPG466]. 2013; <https://www.nice.org.uk/guidance/ipg466>. Accessed February 10, 2021.
19. American Academy of Ophthalmology (AAO). CXL for Corneal Ectasia: Reshaping the Future of Treatment. <https://www.aao.org/eyenet/article/cxl-corneal-ectasia-reshaping-future-of-treatment-2> Accessed September 30, 2022.
20. American Academy of Ophthalmology (AAO). Cornea/External Disease Summary Benchmarks – 2018. AAP PPP Cornea/External Disease Panel, Hoskins Center for Quality Eye Care. Nov 2017. <https://www.aao.org/summary-benchmark-detail/cornea-external-disease-summary-benchmarks-2018>. Accessed September 30, 2022.

*The articles reviewed in this research include those obtained in an Internet based literature search for relevant medical references through September 26, 2023, the date the research was completed.*



### Joint BCBSM/BCN Medical Policy History

| Policy Effective Date | BCBSM Signature Date | BCN Signature Date | Comments  |
|-----------------------|----------------------|--------------------|---|
| 1/1/12                | 10/11/11             | 11/9/11            | Joint policy established  |
| 5/1/13                | 2/19/13              | 3/4/13             | Routine maintenance; BCBSA policy incorporated into updated policy; title changed from “Riboflavin Application with UVA for the Treatment of Keratoconus (Corneal Cross-Linking)” to current title  |
| 11/1/14               | 8/21/14              | 8/25/14            | Routine maintenance   |
| 11/1/15               | 8/24/15              | 9/14/15            | Routine maintenance   |
| 11/1/16               | 8/16/16              | 8/16/16            | Routine maintenance<br>T code replaced NOC code   |
| 11/1/17               | 8/31/17              | 8/25/17            | <ul style="list-style-type: none"> <li>• Routine maintenance</li> <li>• Changed to mixed status</li> <li>• Codes added 65435, 69990, 76514</li> <li>• FDA approval for New Drug Application added</li> </ul>                                      |
| 11/1/18               | 8/21/18              | 8/21/18            | <ul style="list-style-type: none"> <li>• Routine maintenance</li> </ul>   |
| 11/1/19               | 9/20/19              |                    | <ul style="list-style-type: none"> <li>• Routine maintenance</li> <li>• Discussion regarding conservative therapy prior to surgery</li> <li>• Conservative therapy and progression of keratoconus requirements removed from inclusions</li> </ul> |
| 3/1/20                | 12/17/19             |                    | <ul style="list-style-type: none"> <li>• Routine maintenance</li> </ul>   |
| 3/1/21                | 12/15/20             |                    | <ul style="list-style-type: none"> <li>• AMA (2019) clarified that riboflavin is not included in the 0402T code</li> <li>• J2787 (riboflavin added to policy)</li> </ul>  |
| 3/1/22                | 12/14/21             |                    | <ul style="list-style-type: none"> <li>• Routine maintenance</li> </ul>   |
| 3/1/23                | 12/20/22             |                    | <ul style="list-style-type: none"> <li>• Routine maintenance (slp)</li> </ul>   |
| 3/1/24                | 12/19/23             |                    | <ul style="list-style-type: none"> <li>• Routine maintenance (slp)</li> <li>• Vendor managed: N/A</li> </ul>  |

Next Review Date: 4<sup>th</sup> Qtr, 2024

**BLUE CARE NETWORK BENEFIT COVERAGE  
POLICY: CORNEAL COLLAGEN CROSS-LINKING**

**I. Coverage Determination:**

|  |  |
|--|--|
| <b>Commercial HMO (includes Self-Funded groups unless otherwise specified)</b> | Covered; criteria apply  |
| <b>BCNA (Medicare Advantage)</b>   | Refer to the Medicare information under the Government Regulations section of this policy. |
| <b>BCN65 (Medicare Complementary)</b>  | Coinsurance covered if primary Medicare covers the service.                                |

**II. Administrative Guidelines:**

- The member's contract must be active at the time the service is rendered.
- Coverage is based on each member's certificate and is not guaranteed. Please consult the individual member's certificate for details. Additional information regarding coverage or benefits may also be obtained through customer or provider inquiry services at BCN.
- The service must be authorized by the member's PCP except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Services must be performed by a BCN-contracted provider, if available, except for Self-Referral Option (SRO) members seeking Tier 2 coverage.
- Payment is based on BCN payment rules, individual certificate and certificate riders.
- Appropriate copayments will apply. Refer to certificate and applicable riders for detailed information.
- CPT - HCPCS codes are used for descriptive purposes only and are not a guarantee of coverage.